Contemporary approaches for cardiovascular risk reduction in diabetes

Indian Heart Journal

Volumn 61, Issue 1, 2009, Pages 24-33

  Deedwania, Prakash ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cardiology Division   (United States)

^c Program at Fresno   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC OBESITY; DIABETIC RETINOPATHY; DIET THERAPY; DRUG CHOICE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; RISK REDUCTION BEHAVIOR;

EID: 66949117101     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
2. Deedwania P, Srikanth S. Diabetes and vascular disease. Expert Rev Cardiovasc Ther. 2008 Jan;6(1):127-138
3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study. Lancet .2004;364: 937-952. (Pubitemid 39208455)
4. Srikanth S, Deedwania P. Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. Cardiol Clin. 2005. (Pubitemid 40203094)
5. Deedwania PC, Fonseca V. Diabetes , Prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005;118:939-947. (Pubitemid 41297754)
6. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India. 2006 Oct;54:797-810. (Pubitemid 44563740)
7. Gupta R, Deedwania PC, Gupta A, et al. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol. 2004;97(2):257-261 (Pubitemid 39286845)
8. Ruige JB, Assendelft WJ, Dekker JM, et al. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab.1998;83:2772-2776.
9. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998;83:2773-2776 (Pubitemid 28493774)
10. Abbasi F, McLaughlin T, Lamendola C, Reaven GM. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. J Clin Endocrinol Metab 2000;85:1252-1254 (Pubitemid 32269381)
11. Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998;244:361-370 (Pubitemid 28513123)
12. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998;81:47B-51B. (Pubitemid 28113946)
13. Veniant MM, Sullivan MA, Kim SK, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000;106:1501-1510 (Pubitemid 32038588)
14. Stamler J, Vaccaro I, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444 (Pubitemid 23046633)
15. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non- insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828 (Pubitemid 28112428)
16. Stamler J, Vaccaro I, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444 (Pubitemid 23046633)
17. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study(UKPDS: 23). BMJ 1998;316:823-828 (Pubitemid 28112428)
18. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care.1990;13:153-169. (Pubitemid 20056205)
19. Pyorola K, Pederson TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620. (Pubitemid 27143424)
20. Goldberg RB, Mellies MJ, Sacks FM, et al for the CARE investigators.Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-2519. (Pubitemid 29001188)
21. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlld trial. Lancet. 2003 Jun 14;361(9374):2005-2016
22. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004 Aug 21;364(9435):685-696
23. Rubins HB, Robins SJ, Collins D, et al for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
25. Grundy SM, Cleeman JI, Bairey Merz CN, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110:227-239.
26. Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-357 (Pubitemid 17118813)
27. Swislocki ALM, Hoffman BB, Raven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989;2:419-423 (Pubitemid 19168223)
28. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications of type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713. (Pubitemid 28414300)
29. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
30. Wright JT Jr, Jones DW, Green LA, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA 2003;289:2560-2571
31. G.L. Bakris, M. Williams, L. Dworkin et al., Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36(3):646661.
32. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy [published correction appears in Lancet 2000;356:850]. Lancet 2000;355:253-259.
33. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
34. Poulter N, Williams B. Doxazosin for the management of hypertension: implicationsof the findings of the ALLHAT Trial. Am J Hypertens 2001;14:1170-1172. (Pubitemid 33033119)
35. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853. (Pubitemid 28416718)
36. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
37. Khaw KT, Wareham N, Luben R, et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001 Jan 6;322(7277):15-18. (Pubitemid 32066250)
38. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003 Mar;26(3):688-696 (Pubitemid 36929329)
39. Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2002;357:89-95.
40. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2003 Jan;26(Suppl 1):S87-8.
41. U.S. Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2001;136:157-160.
42. Antithrombotic Trialists' Collaboration: Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. (Pubitemid 34073138)
43. Hansoson K, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
44. Bhatt D, Marso S, Hirsh A, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-628 (Pubitemid 35264538)
45. American Diabetes Association. Standards of Medical Care in Diabetes- Position Statements Original Article. Diabetes Care 27:S15-S35, 2004.
46. JNC VII. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The Seventh Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). JAMA 2003;289(19):2560-2572.
47. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults.Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatmetn of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2002;285:2486-2497
48. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report published by the National Institutes of Health, National Heart, Lung, and Blood Institute in June 1998.
49. Lauber RP, Sheard NF; American Heart Association. The American Heart Association Dietary Guidelines for 2000: a summary report. Nutr Rev. 2001 Sep;59(9):298-306
50. Gaede P, Vedel P, Larsen N, et al. Mutlifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
51. Lindstrom J, Eriksson JG, Valle TT, et al . Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S108-13. (Pubitemid 36750503)
52. The DPP Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346:393403.
53. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-'NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus:'the STOP-NIDDM randomised trial. Lancet 2002; 359: 20727.
54. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. 2004;109(1):2-4.
55. Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group.Effects of intensiveglucose lowering in type 2 diabetes. N Engl J Med 2008;358:2547-2559.
56. The ADVANCE Collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
57. Skyler JS, Bergenstal R, Bonow R, et al. Position Statement: Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VADT. Diabetes Care 2009;32:187-192.